Speedy BSE test pushes up Proteus shares
Friday 21 February 1997
Shield Diagnostics' share price was also strong, rising 80p to 416.5p, after it revealed a research tie-up with Abbott Laboratories, the US pharmaceuticals group. However, investors reacted negatively to news that plans by Phytopharm to develop a plant-based cure for eczema would be delayed by around two years. The shares fell 23p to 185.5p.
Proteus said Enfer Scientific, an Irish licensee, had produced a high- throughput test for BSE based on a reagent produced by the British firm which had been validated by the Irish Department of Agriculture. David Gration, chairman, said the department's agricultural veterinary research laboratory was "happy to validate that this test does successfully discriminate between positive and negative BSE carcasses".
The post mortem test was capable of processing 1,000 samples at a time and could be used in slaughterhouses, he said. Proteus went through a bad patch last year after raising pounds 9.5m in a rights issue and seeing then chief executive, Jurek Sikorski, resign soon after.
But Mr Gration said Proteus had signed a deal with Enfer which would net Proteus 12.5 per cent of any revenues earned from the test, which analysts believe could give the company income running into seven figures.
Shield, meanwhile, said it had signed an exploratory research agreement with the diagnostics division of Abbott Laboratories. This would give it access to Abbott's instruments, reagents and training in developing new hospital diagnostic tests, the company said.
The problems of Phytopharm, whose technology is based on Chinese herbal remedies, concern its Zemaphyte drug for severe atopic eczema, a skin complaint. UK approval for the product, currently in phase three trials with 150 patients, will be delayed for around 18 months after US tests begin in September, according to Richard Dixey, chief executive.
This was due to concerns expressed by the British Medicines Control Agency.
But Mr Dixey played down the delays, saying they wouldhelp improve the chances for the drug, given that regulators on both sides of the Atlantic were now in closer liaison and the company had a clearer target to aim for.
- 1 Raif Badawi, the Saudi Arabian blogger sentenced to 1,000 lashes, may now face death penalty
- 2 Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
- 3 PornHub turns masturbation into energy in bid to save the planet
- 4 Have sex with your iPad thanks to the new sex toy no-one asked for
- 5 Spiritual leader allegedly manipulated 400 men into removing testicles to be 'closer to God'
Raif Badawi, the Saudi Arabian blogger sentenced to 1,000 lashes, may now face death penalty
Delhi bus rapist blames dead victim for attack because 'girls are responsible for rape'
PornHub turns masturbation into energy in bid to save the planet
Spiritual leader allegedly manipulated 400 men into removing testicles to be 'closer to God'
The 'sex selfie stick' lets you FaceTime the inside of a vagina
New theory could prove how life began and disprove God
This is what it's like to be dead, according to a guy who died for a bit
End of the licence fee: BBC to back radical overhaul of how it is funded
'Jihadi John': CAGE representative storms off Sky News accusing Kay Burley of Islamophobia
Ukip would cut billions from Scottish budget to fund English tax cuts
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
iJobs Money & Business
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£15000 - £16000 per annum: Recruitment Genius: A Customer Service Advisor is r...
£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...
£40000 - £50000 per annum + pro rata: SThree: SThree Group have been well esta...